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The effects of higher hemoglobin levels on mortality and hospi- in 1989 to treat the anemia of chronic renal failure marked
talization in hemodialysis patients. a major milestone in nephrology clinical practice [1]. Sev-
Background. The introduction of recombinant human eryth- eral studies have shown that treatment of anemia withropoietin for the treatment of anemia of chronic renal failure
rHuEPO leads to overall improvements in quality of life,provided the opportunity to correct anemia in this patient
increased exercise capacity, decreased sleep disturbances,population. The optimal target hemoglobin for patients with
end-stage renal disease (ESRD) remains controversial. A large and improved cognitive function in end-stage renal dis-
database of hemodialysis patients was analyzed to determine ease (ESRD) patients [2–8]. Anemia is considered to be
whether increasing hemoglobin level above the current Kidney one of the important risk factors in the development ofDialysis Outcomes Quality Initiative (K/DOQI) recommenda-
left ventricular hypertrophy (LVH), a major contributortions was associated with increased risk of mortality and hospi-
to cardiac mortality and morbidity in ESRD patients [9].talization.
Methods. A longitudinal study of hemodialysis patients in The use of rHuEPO to raise hemoglobin levels in ESRD
Fresenius Medical Care–North America facilities was per- patients leads to partial regression of LVH, and improve-
formed. Selection was restricted to patients in the census for
ment in other cardiovascular conditions that accompany6 consecutive months from July 1, 1998 through June 30, 2000.
chronic renal failure [2, 9–11].Patient mean hemoglobin and other covariates measured dur-
ing the initial 6 months were related to survival, number of While these benefits of anemia treatment have been
hospitalizations, and length of stay over the subsequent 6 well established, the optimal target hemoglobin for ESRD
months of follow-up. patients has remained controversial. The publication of
Results. Patients with hemoglobin 9 g/dL had an adjusted
the National Kidney Foundation Dialysis Outcomes Qual-relative risk of death of 2.11 compared to those patients with
ity Initiative (NKF-DOQI); now known as Kidney Dis-11 hemoglobin 12 g/dL (P 0.0001). The adjusted relative
risk of death was 0.84 for 12  hemoglobin  13 g/dL (P  ease Outcomes Quality Initiative or K/DOQI Clinical
0.007). These data suggest there is no increased risk of mortality Practice Guidelines for Anemia of Chronic Renal Failure
associated with hemoglobin above the current recommended recommended a target hemoglobin of 11 g/dL to 12 g/dLvalues. Both number of hospitalizations and length of stay
(corresponding to a hematocrit of 33% to 36%), baseddecreased as hemoglobin increased. Patients with hemoglobin
on the available evidence [1, 12]. In hormone deficiency13 g/dL had an adjusted length of stay of 9.6 days compared
to 10.9 days for those with 11  hemoglobin  12 g/dL (P  states, generally the treatment goal is to correct the defi-
0.0001). ciency, if possible; partial correction of the hormone
Conclusion. These data indicate the relative risk of death deficiency is rarely a treatment goal. Thus, greater pa-and hospitalization are inversely associated with hemoglobin
tient benefit may be obtained by normalization of hemo-levels, with no apparent additional risk associated with hemo-
globin levels (i.e., achieving values 12 g/dL for womenglobin levels  12 g/dL.
and 13 g/dL for men) [13, 14].
A study of prevalent Medicare ESRD patients receiv-
The anemia of chronic renal failure is primarily due ing rHuEPO showed a statistically significant (P 0.001)
to a deficiency of endogenous erythropoietin. The intro- higher risk of all-cause mortality when hematocrit was
duction of recombinant human erythropoietin (rHuEPO) 33% (hemoglobin 11 g/dL) compared to the refer-
ence value of 33% to 36% [15]. The number of patients
with hematocrit 36% was small (N  685), therebyKey words: hemoglobin, mortality, hospitalization, anemia, erythropoi-
etin, hemodialysis. reducing the ability to detect if there was any survival
benefit to patients with hematocrit 36% (hemoglobinReceived for publication September 12, 2002
12 g/dL). Additional analyses of the same Medicareand in revised form November 27, 2002
Accepted for publication January 3, 2003 database showed a statistically significant (P  0.0001)
reduction in the risk of hospitalization when hematocrit 2003 by the International Society of Nephrology
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was 33% to 36%, compared to hematocrit 33% [16]. for each patient. The addition of hemoglobin2 (a qua-
dratic model in hemoglobin) as an independent variableIn 2001, using an incident ESRD patient cohort, Collins
et al [17] reported further reduction in the relative risk was designed to highlight the potential for hemoglobin
to have a nonlinear risk profile. Specifically, the quadraticof mortality and hospitalization in those patients with
hematocrit 36% to39% compared to the reference value may enhance the appearance of a U-shaped risk profile,
in case hemoglobin has a negative effect at both extremelyof 33% to 36%. However, the difference for mortality
was not statistically significant between the reference low and high values. Analyses were performed (1) using
only hemoglobin and hemoglobin2 as independent vari-group and the categories of 36% to 39% and 39%.
In contrast, the relative risk of hospitalization in patients ables and (2) using hemoglobin and hemoglobin2 plus the
additional covariates age, race, gender, diabetes, BMI, al-with hematocrit of 36% to39% and39% was signifi-
cantly lower compared to the reference group. However, bumin, missed treatments, and URR. To further explore
any nonlinear relationship between survival and hemoglo-a randomized controlled clinical trial in a high-risk group
of hemodialysis patients with significant cardiac disease bin, the same models were examined using the six hemoglo-
bin categories, or hemoglobin9 g/dL, 9 hemoglobinsuggested that targeting hemoglobin to normal levels
did not confer benefit (intent-to-treat analysis) [18]. The 10 g/dL, 10  hemoglobin  11 g/dL, 11  hemoglo-
bin  12 g/dL, 12  hemoglobin  13 g/dL, and hemo-recommendation from the trial was that hemodialysis
patients with clinically evident heart disease should not globin 13 g/dL in place of the continuous variables
hemoglobin and hemoglobin2.have hematocrit raised to a normal value (42% or hemo-
globin 14 g/dL). Therefore, further examination of hemo- The primary outcomes measured in the study were
mortality, time to death, number of hospitalizations, andglobin concentrations in a large group of ESRD patients
might be useful in evaluating the relative risk of adverse total length of hospital stay. These outcomes were con-
sidered only for the 6 months following the baselineoutcomes, such as mortality and hospitalizations with
higher hemoglobin levels. entry period. They were analyzed as functions of mean
hemoglobin concentration during the baseline period.Fresenius Medical Care North America (FMCNA) is
a dialysis provider that treated approximately 125,000 The patient’s time to death was censored at the earlier
of (1) date of permanent discharge from FMCNA orESRD patients in more than 900 facilities in the United
States during the period July 1998 to June 2000. FMCNA (2) the end of the 6-month follow-up period. The total
hospital length of stay and the number of hospitalizationsmaintains an extensive database of demographic, treat-
ment, and laboratory data on all patients. The purpose were considered only for a patient’s follow-up period.
Since some patients died or otherwise left the systemof this study was to analyze this database to evaluate
the association of hemoglobin level with mortality, inci- during the follow-up period, the total hospital length of
stay and number of hospitalizations were estimated perdence of hospitalization, and length of hospital stay in
ESRD patients. 6 months of follow-up by performing a weighted analysis
in which the weight was proportional to the fraction of
the follow-up for which the patient was observed.METHODS
The analyses for number of hospitalizations and total
This was a retrospective, longitudinal study of ESRD hospital length of stay were based on the same models
patients in the FMCNA database. The selection for anal- used in the survival analyses: (1) using only hemoglobin
ysis was restricted to patients who were in the census and hemoglobin2 (or the six hemoglobin categories) as
for at least 6 consecutive months (baseline) during the independent variables and (2) using hemoglobin and
period July 1, 1998 through June 30, 2000. Data were hemoglobin2 (or the six hemoglobin categories) plus the
available for patient age, gender, race, presence of diabe- additional covariates age, race, gender, diabetes, BMI,
tes (yes, no), time on dialysis (vintage), height and weight albumin, missed treatments, and URR.
from which body mass index (BMI) was calculated, and Analyses of survival were performed using PROC
missed treatments (more than one electively missed treat- PHREG and PROC LIFETEST (SAS 8.2; SAS Institute,
ment in a 6-month period). Selected laboratory variables Cary, NC, USA). Poisson analyses of hospital length of
also were analyzed, including hemoglobin, albumin, trans- stay and number of hospitalizations were performed us-
ferrin saturation, and urea reduction ratio (URR, %). ing PROC GENMOD (SAS 8.2; SAS Institute, Cary,
Data were not available on prevalence or severity of NC, USA).
comorbid conditions in the population or iron adminis-
tered during the baseline or follow-up period.
RESULTSThe covariates used in the analyses were hemoglobin,
age, race, gender, and diabetes status, BMI, albumin, Basic demographic descriptors of the population in-
cluded in these analyses are shown in Table 1. As canmissed treatments, and URR. Laboratory variables were
based on averaging the baseline (i.e., first 6 months) data be seen, there were 44,550 patients eligible for inclusion
Ofsthun et al: Hemoglobin, mortality, and hospitalization1910
Table 2. Clinical and biochemical parameters for patient populationTable 1. Demographics of patient population
Age MSD 59.7315.3 Mean/median
Standard observationsGender, females number 21,276 (47.8%)
Race, African Americans number 16,966 (38.1%) Parameter Mean error per patient
Diabetes number 21,326 (47.9%)
Time on dialysis months 25.4 0.17 NABMI MSD 25.836.03
rHuEPO dose U/weeka 17,824 48 22/25 weeksTotal 44,550
Median dose U/week  16,300
Hemoglobin g/dLa 11.2 0.005 17/15
Albumin g/dLa 3.8 0.002 6/6
Urea reducation ratio %a 68.95 0.03 6/6
Transferrin saturation %a 29.3 0.05 5/6
in the data set. This sample represents approximately
a Data obtained for first 6 months of study
36% of all ESRD patients treated in FMCNA facilities
during the time period. The population had a mean age
of 59.7 years, with 38.1% of patients designated as Afri-
can Americans. Males were the majority (53.2%) and highest two hemoglobin categories, thus supporting a
approximately half of the patients had been diagnosed quadratic model in hemoglobin when adjusting for the
with diabetes. BMI averaged 25.83 kg/m2. other covariates.
As shown in Table 2, patients had a mean vintage of To examine the impact of hemoglobin on time to
25.4 months. Mean hemoglobin was 11.2 on an average death, Kaplan-Meier plots were constructed for each of
weekly dose of rHuEPO of 17,824 units. Albumin aver- the hemoglobin categories (Fig. 2). These data showed
aged 3.8 and mean URR was above the K/DOQI mini- a progressive improvement in the proportion of patients
mum value. Average transferrin saturation was 29.3%. surviving as a function of the hemoglobin category. Pa-
The last column in Table 2 shows the mean observations tients with hemoglobin 9 g/dL had the lowest propor-
per patient for each parameter. tion of patients surviving, and those patients with hemo-
Patients were stratified by mean hemoglobin concentra- globin 13 g/dL had the highest proportion of patients
tion (Table 3). There was a higher proportion of African surviving across time. The results from this analysis dem-
American and female patients in the lower hemoglobin onstrate a positive relationship between survival at the
strata, while diabetic patients were equally distributed
end of follow-up and higher hemoglobin level. The esti-
across hemoglobin categories. Mean albumin was higher
mated survival at the end of the 6-month follow-up pe-in the upper hemoglobin categories as was transferrin
riod is shown in Table 4.saturation. The URR was similar across all hemoglobin
For the number of hospitalization analyses, the coeffi-strata. Mean rHuEPO dose decreased as hemoglobin
cients for both hemoglobin and hemoglobin2 were signifi-increased.
cant in each analysis (P  0.0002). To further explore theUsing hemoglobin as a continuous variable for the
relationship between number of hospitalizations and hemo-first (unadjusted) analysis of mortality, only the coeffi-
globin, the same models were examined using the six hemo-cient for hemoglobin (linear model) was significant (P
globin categories in place of the continuous variables he-0.0001); for the quadratic term, P  0.7. For the second
moglobin and hemoglobin2. The expected average number(adjusted) analysis, both coefficients were significant: P
of hospitalizations for the 6-month study period de-0.001 and P  0.044, respectively.
creased monotonically from 3.62 for the group with he-To further describe the relationship between patient
moglobin9 g/dL to 1.44 for the group with hemoglobinsurvival and hemoglobin, the relative risk of death was
13 g/dL, although this reduction was not as pronouncedplotted versus six hemoglobin categories in unadjusted
after adjustment for covariates: 2.45 to 1.65 (Fig. 3).and adjusted models (Fig. 1). These analyses revealed
For the hospital length of stay analyses, the coefficientsthat patients with hemoglobin 9 g/dL had an adjusted
for both hemoglobin and hemoglobin2 were significantrelative risk of death of 2.11 compared to the reference
in each analysis: P  0.0001 for the linear term in bothvalue for 11 hemoglobin 12 (P 0.0001). The relative
analyses, and P  0.04 and P  0.03, respectively, forrisk of death continued to decrease as hemoglobin levels
the quadratic terms. To further explore the relationshipincreased, with adjusted relative risk of death of 0.84 for
between length of stay and hemoglobin, the same modelsthe group with 12  hemoglobin  13 g/dL (P  0.007),
were examined using the six hemoglobin categories inand 0.82 (P  NS) for the group with hemoglobin 13
place of the continuous variables hemoglobin and hemo-g/dL compared to the reference group of 11 hemoglo-
globin2. The expected average length of stay for thebin  12 g/dL. The results support the adequacy of the
6-month study period decreased monotonically from 22.0assumption of linear fit of relative risk of death as a
average number of days per patient for the group withfunction of hemoglobin level unadjusted for the addi-
hemoglobin9 g/dL to 9.1 days for the group with hemo-tional covariates (Fig. 1). In the adjusted model (Fig. 1),
the decrease in relative risk appeared to flatten for the globin13 g/dL in the unadjusted analysis (Fig. 4). After
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Table 3. Characteristics of patient population stratified by hemoglobin levels
Hemoglobin g/dL 9 9 to 10 10 to 11 11 to 12 12 to 13 13
Number 1607 4268 11790 18758 6670 1457
Mean age years 54.8 51.8 56.9 59.7 61.0 58.0
African American % 59.3 47.2 40.9 35.2 31.8 28.2
Female % 55.3 55.3 52.2 47.0 39.0 30.6
Vintage years 1.9 1.63 1.66 1.71 1.47 1.99
Diabetic % 37.4 46.8 49.0 48.6 48.2 43.2
Mean albumin 3.50 3.58 3.72 3.82 3.83 3.87
Mean % transferrin saturation 28.61 25.88 27.60 30.21 31.53 31.98
Mean urea reduction ratio 66.15 67.15 68.64 69.71 69.28 68.52
Mean rHuEPO U/week 26,700 24,700 20,400 15,700 13,600 12,800
Mean rHuEPO U/kg/week 392 368 299 229 197 181
Mean hemoglobin 8.36 9.59 10.57 11.47 12.36 13.64
rHuEPO is human recombinant erythropoetin.
Fig. 2. Kaplan-Meier analysis of patient survival (unadjusted for covar-
iates). The overall test of significance for differences among the six
curves is P .0001. All pair-wise comparisons among the curves (unad-
justed for multiplicity) have P values 0.025 except for the curves
representing categories 12  hemoglobin (Hgb)  13 g/dL, and 13
g/dL (P  0.37).
Fig. 1. Patient survival versus hemoglobin (Hgb) level, unadjusted and
adjusted for covariates. Relative risk of death in the 6-month follow- exercise capacity [22, 23], and cognitive function [6–8].up period for each group based on hemoglobin levels during the study
Many of these studies examined patients with hemoglo-baseline. Values were adjusted for age, race, gender, diabetes, body
mass index (BMI), albumin, missed treatments, and urea reduction ratio bin levels in the range of 10 to 11 g/dL (corresponding
(URR). The reference value for the analysis was 11  hemoglobin  approximately to hematocrit levels between 30% to12. *Statistically significant difference from reference; 95% CI intervals
33%), and only recently has attention focused on poten-shown.
tial benefits of normalizing hemoglobin (hemoglobin
12 g/dL). A hematocrit normalization study in 1200
hemodialysis patients with significant preexisting cardiac
adjustment for covariates, the decrease was from 16.2 disease (congestive heart failure and/or ischemic cardiac
days to 9.6 days (Fig. 4). disease) was stopped after an interim analysis indicated
that there were more deaths in the group randomized
DISCUSSION to achieve a target hematocrit of 42% compared to the
group with a target hematocrit of 30% [18]. However,The anemia of chronic renal failure develops in the
mortality rates decreased with increasing hematocrit val-early stages of kidney failure, yet management of anemia
ues in both normal hematocrit and low hematocritis suboptimal for a large proportion of patients [19].
groups. The results were further potentially confoundedEarly management of anemia can lead to a reduction in
by other variables such as dialysis adequacy (Kt/V),the severity of comorbid conditions and may slow the
which declined in the high hematocrit group, and moreprogression of renal failure [20]. Several studies in ESRD
frequent iron dextran infusions required to achieve thepatients have demonstrated that correcting anemia with
higher hematocrit target. It is not possible to explain therHuEPO has significant benefits, including improvement
in quality-of-life indicators [2, 4], cardiac status [11, 21], difference in observed results between the randomized
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Table 4. Kaplan-Meier survival rates at the end of the second 6 months versus hemoglobin category
Lower limit Upper limit
Hemoglobin category 95% CI Survival rate 95% CI Number
Hemoglobin 9 g/dL 0.819 0.838 0.856 1607
9  hemoglobin  10 g/dL 0.849 0.860 0.871 4268
10  hemoglobin  11 g/dL 0.890 0.896 0.901 11790
11  hemoglobin  12 g/dL 0.923 0.926 0.930 18758
12  hemoglobin  13 g/dL 0.931 0.937 0.943 6670
Hemoglobin 13 g/dL 0.931 0.943 0.955 1457
Fig. 3. Number of hospitalizations versus hemoglobin (Hgb) level, un-
Fig. 4. Total hospital length of stay versus hemoglobin (Hgb) level,adjusted and adjusted for covariates. The number of hospitalizations
unadjusted and adjusted for covariates. Total hospital length of stayper 6 months follow-up for each group based on hemoglobin levels
per 6 months follow-up for each group based on hemoglobin levelsduring the study baseline. Values were adjusted for age, race, gender,
during the study baseline. Values were adjusted for age, race, gender,diabetes, body mass index (BMI), albumin, missed treatments, and urea
diabetes, body mass index (BMI), albumin, missed treatments and ureareduction ratio (URR). The reference value for the analysis was 11 
reduction ratio (URR). The reference value for the analysis was 11 hemoglobin  12. The number of hospitalizations was calculated by
hemoglobin 12. The length of hospital stay was calculated by weightedweighted analysis with the weights proportional to the length of time
analysis with the weights proportional to the length of time a subject wasa subject was observed during the 6 months follow-up period. *Statisti-
observed during the 6 months follow-up period. *Statistically significantcally significant difference from reference; 95% CI intervals shown.
difference from reference; 95% CI shown.
trial and the associations in the retrospective analyses. absence of severe ischemic cardiac disease or heart fail-
The randomized trial selected only patients with existing ure. The study of prevalent Medicare ESRD patients
heart disease, including 19% of patients with congestive examined mortality over a 12-month period based on
heart failure, New York Heart Association Class 3. In hematocrit levels over the preceding 6 months. The anal-
general, the trial patients were older (65 years of age) yses were adjusted for a number of comorbid conditions.
with more coexisting diseases compared to the general Patients with hematocrit30% (hemoglobin10.0 g/dL)
dialysis population. The FMCNA database analyzed for had the greatest risk of all-cause and cause-specific death,
this report included only those patients that survived for and there was a further reduction in risk for patients
at least 6 consecutive months, and data were not avail- with hematocrit between 33% and 36% (hemoglobin of
able on comorbid conditions. Based on the results of the 11 to 12 g/dL) [15]. Additional analyses showed that
randomized trial, electively raising hematocrit to normal patients with hematocrit 30% had the highest risk of
levels in patients with existing cardiac disease is not rec- future hospitalization, while those with hematocrit be-
ommended. tween 33% and 36% had the lowest risk [16]. These
Recent studies indicate that raising hemoglobin levels results were extended by subsequent analyses of incident
into the lower end of the normal range does not appear Medicare ESRD patients showing that for patients with
hematocrit 36% to 39%, mortality rates were not dif-to pose additional risk to ESRD patients in the apparent
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ferent, but hospitalization rates were 16% to 22% lower, While raising hemoglobin levels to the range recom-
compared to patients with hematocrit of 33% to 36% mended by the K/DOQI guidelines should be the goal
[17]. In addition, Medicare Part A and B expenditures for every patient, additional benefits may be obtained
were 8.3% to 8.5% less over the 1-year follow-up when by targeting higher hemoglobin levels (12 g/dL for
hematocrit was 36% to 39%, compared to 33% to females and 13 g/dL for males) in some patients. Be-
36%, which could represent significant savings to the cause of variability in patient physiologic parameters,
Medicare program. Expenditure estimates for the differ- optimal anemia management will require an individual-
ent hemoglobin categories were not available for inclu- ized approach to patients [14]. Mortality risk, time to
sion in this analysis. death, number of hospitalizations, and length of hospital
The results reported here support the conclusions stay, at least for the short term, do not appear to be
drawn from the Medicare ESRD patient studies. Patients worse when hemoglobin exceeds 12 g/dL compared to
with hemoglobin 9 g/dL had the lowest 6-month sur- the reference group of 11 to 12 g/dL in this large cohort
vival rate of all groups, and survival rates increased with of hemodialysis patients.
increasing hemoglobin levels. Unadjusted relative risk There are several limitations of this study. It is a retro-
of death decreased as hemoglobin levels increased, al- spective descriptive study based on observations and does
though the difference was smaller for the groups with not infer causality between hemoglobin and selected out-
12  hemoglobin 13 g/dL and hemoglobin 13 g/dL comes. The follow-up period was only 6 months, and
after adjustment for covariates. The small patient sample ESRD patients had to survive for at least 6 months dur-
for the hemoglobin 13 g/dL limited the probability of ing the observation period to be included in the sample,
demonstrating further reduction in relative risk of death. which may have introduced selection bias, as well as
Patients in the hemoglobin categories 12.0 g/dL may limiting generalizability.
be the group of patients with fewer comorbidities and It should also be noted that comorbid conditions were
thus able to achieve higher hemoglobin levels. However, not available to use in the adjusted analyses. It has been
these data suggest that there is no increased risk of mor- observed that hemodialysis patients with more severe
tality associated with hemoglobin higher than the values coexisting conditions may also be those patients in the
recommended by the K/DOQI guidelines and, perhaps, lower hemoglobin categories, and the analyses reported
some decreased risk. Furthermore, these data show that here could not adjust for those conditions. Observational
higher hemoglobin correlates with reduced hospital length
studies are subject to confounding by unmeasured fac-
of stay, suggesting that an improvement in anemia status
tors, such as the comorbid conditions cited above. There-may be beneficial to hospitalized patients. There was no
fore, observational studies should be confirmed or dis-increase in either number of hospitalizations or hospital
confirmed by well-designed experimental studies.length of stay over the 6-month follow-up period for
In the absence of direct adverse outcomes related togroups with hemoglobin 12 g/dL, indicating that ane-
hemoglobin 12 g/dL, specific benefits leading to im-mia correction to hemoglobin levels 12 g/dL did not
provement in biochemical parameters, ease of patientappear to pose additional risks for ESRD patients. Longer
management, and quality of life may be further explored.follow-up beyond 6 months might demonstrate longer-
These data support the need for prospective studies withterm benefit by reducing LVH and/or cardiac dilatation.
longer follow-up to demonstrate the potential benefitsAlthough cardiovascular comorbidities were not col-
of higher hemoglobin levels in ESRD patients as appro-lected for these analyses, there is evidence from a small,
priate in those without apparent severe cardiovascularmulticenter Canadian study of hemodialysis patients that
disease or heart failure.normalization of hemoglobin levels can prevent progres-
sive LV dilation [11]. The study also concluded that nor- Reprint requests to J. Michael Lazarus, M.D., Fresenius Medical
malization of hemoglobin may lead to improved quality Care—North America, 95 Hayden Avenue, Lexington, MA 02420.
E-mail: michael.lazarus.md@fmc-na.comof life. Another small study demonstrated that raising
hemoglobin levels to 14 g/dL (compared to a baseline of
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